Theralase Technologies (CVE:TLT) Shares Up 14.3% – Time to Buy?

Theralase Technologies Inc. (CVE:TLTGet Free Report)’s share price was up 14.3% during trading on Tuesday . The company traded as high as C$0.28 and last traded at C$0.28. Approximately 280,000 shares were traded during trading, an increase of 143% from the average daily volume of 115,417 shares. The stock had previously closed at C$0.25.

Theralase Technologies Price Performance

The business has a fifty day moving average price of C$0.27 and a 200 day moving average price of C$0.23. The company has a market cap of C$68.75 million, a price-to-earnings ratio of -14.00 and a beta of 1.36. The company has a debt-to-equity ratio of 20.58, a quick ratio of 3.40 and a current ratio of 1.21.

Theralase Technologies Company Profile

(Get Free Report)

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

See Also

Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.